Inhibikase Therapeutics, Inc.

IKT · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$27,520-$19,029-$18,054-$14,786
Dep. & Amort.$26$177$7$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$8,141$500$458$1,532
Change in WC$205$235$171-$1,764
Other Non-Cash$0$32$67$722
Operating Cash Flow-$19,148-$18,085-$17,351-$14,297
Investing Activities
PP&E Inv.$0-$14-$243$0
Net Acquisitions$0$0$243$0
Inv. Purchases-$60,455-$29,426-$20,725$0
Inv. Sales/Matur.$23,451$41,097$4,963$0
Other Inv. Act.$0$0-$243$0
Investing Cash Flow-$37,004$11,657-$16,006$0
Financing Activities
Debt Repay.$0$0-$249-$43
Stock Issued$103,478$8,544$44$41,135
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$139$0$1
Financing Cash Flow$103,478$8,405-$205$41,094
Forex Effect$0$0$0$0
Net Chg. in Cash$47,325$1,977-$33,562$26,797
Supplemental Information
Beg. Cash$9,165$7,189$40,750$13,954
End Cash$56,491$9,165$7,189$40,750
Free Cash Flow-$19,148-$18,099-$17,594-$14,297